1. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
- Author
-
Monica Bocchia, Angela Michielutti, Luigi Gugliotta, Donatella Raspadori, Maurizio Castelli, Renato Fanin, Paolo Avanzini, Domenico Russo, Alessandro Bonini, Giancarla Pricolo, Alfonso Zaccaria, M Malagola, Eliana Zuffa, Nicoletta Testoni, Francesco Lauria, Antonio De Vivo, Patrizio Mazza, Pier Paolo Piccaluga, Michele Baccarani, Emanuela Ottaviani, Anna Candoni, Mauro Fiacchini, Daniela Damiani, Giuseppe Visani, Michela Rondoni, Giovanni Martinelli, Russo D, Malagola M, Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, and Baccarani M
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,FLAI ,Acute myeloid leukaemia ,Fludarabine ,Multidrug resistance ,Therapy ,Transplantation, Autologous ,Gastroenterology ,Leukocyte Count ,Autologous stem-cell transplantation ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Mucositis ,medicine ,Humans ,Idarubicin ,Prospective Studies ,Etoposide ,Mitoxantrone ,business.industry ,Remission Induction ,ICE ,Cytarabine ,Hematology ,Middle Aged ,medicine.disease ,Surgery ,Transplantation ,Treatment Outcome ,Leukemia, Myeloid ,Karyotyping ,Acute Disease ,Female ,business ,Vidarabine ,Stem Cell Transplantation ,ACUTE MYELOID LEUKAEMIA ,medicine.drug - Abstract
Summary Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared the efficacy and toxicity of FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly diagnosed AML patients
- Published
- 2005